一分钟看懂
这是一项关于前列腺癌的III 期研究，登记的药物或干预包括68-Ga-NYM032，当前状态为招募中。登记地点显示中国南京、无锡有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
68-Ga-NYM032 · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Affiliated Drum Tower Hospital, Medical School of Nanjing University · 南京
- Affiliated Hospital of Jiangnan University · 无锡
公开的入选条件
- 1. Patient is male and aged \>18 years old.
- 2. Participants with histopathologically confirmed prostate adenocarcinoma, who present with elevated PSA and suspected recurrence following radical prostatectomy and/or radiotherapy and/or other radical prostate cancer treatments (e.g., proton therapy, cryoab
- 1. Post-radical prostatectomy (RP): PSA ≥0.2 ng/mL on two consecutive measurements obtained ≥6 weeks after surgery;
- 2. Post-radiotherapy (as defined by the ASTRO-Phoenix consensus): PSA rise ≥2 ng/mL above the PSA nadir;
- 3. Participants with recurrence after other treatments: PSA rise ≥2 ng/mL above the PSA nadir.
- 3. ECOG performance status 0-2; expected survival ≥ 6 months.
- 4. Ability to understand a written informed consent document, and the willingness to sign it.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07649122；登记信息更新于 2026-09-15。